Our company triumphed outright at the "Jilin Province Pharmaceutical Inspection and Testing Technology Competition."

　　To implement and carry forward Jilin Province’s “One Core, Six Duals” high-quality development strategy, the provincial drug administration bureau organized the “Jilin Province Drug Inspection and Testing Technology Competition” in December 2021. This event aimed to comprehensively strengthen the capacity-building of drug inspection and testing in Jilin Province, encourage pharmaceutical manufacturers to enhance their own testing capabilities, and foster a robust culture of "dedication to expertise, respect for skills, scientific rigor, and relentless pursuit of excellence" across drug-producing enterprises and inspection agencies throughout the province. By doing so, the initiative seeks to further promote the effective implementation of drug safety responsibilities among enterprises, inspection institutions, and regulatory authorities, ultimately providing reliable technical support and assurance for public medication safety and the province’s high-quality industrial growth.

　　In the competition among 217 pharmaceutical companies across the province, our company sent Zhang Jing, Wang Ye, and Zhan Yuexia.

　　Tang Huajie and his three teammates advanced steadily, growing stronger with each challenge, before ultimately emerging victorious to claim the championship.

　　This "Grand Competition," the most extensive, far-reaching, and high-profile professional event in the province in recent years—drawing participation from the largest number of enterprises and personnel, while showcasing the highest level of technical expertise—is a concrete action to implement the "four strictest requirements" for pharmaceutical safety. It also serves as a comprehensive review of our province's foundational efforts toward high-quality development of the pharmaceutical industry. Moreover, it highlights the leading role of our province's top-tier pharmaceutical inspection and testing institutions, demonstrating their critical technical guidance capabilities, as well as evaluating their capacity to host large-scale, specialized events. Finally, it provides an important assessment of pharmaceutical manufacturers across the province, underscoring their commitment to strengthening GMP practices, rigorously fulfilling their primary responsibilities for drug quality, and continuously enhancing their technical capabilities in inspection and testing.

　　Honors and achievements are not the终点—they are merely the starting point. We will uphold the principle consistently championed by our Chairman, Mr. Duan Chengjun: "Quality is the lifeblood of our enterprise," as well as the stringent work requirement he has set for our quality inspection team: "There’s absolutely no room for carelessness when it comes to quality." Together, we’ll strive to enhance our capabilities in pharmaceutical testing, working hand-in-hand with drug regulatory authorities to safeguard public medication safety. Our ultimate goal is to produce high-quality, highly trusted, and market-leading drugs, thereby making an even greater contribution to the high-quality development of Jilin Province’s pharmaceutical industry.